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BRAF Mutation and Its 
Importance in Colorectal Cancer
Lee-Jen Luu and Timothy J. Price
Abstract
BRAF mutation is seen in nearly one in ten patients with advanced colorectal 
cancer. Despite major improvements in survival for advanced colorectal cancer 
overall, patients with BRAF mutation continue to have a very poor prognosis 
often with median survival of less than 12 months. It is important for clinicians 
to be aware of this subgroup as the treatment approach should be different. 
Treatment options beyond standard chemotherapy are crucial to achieve bet-
ter outcomes and the role of anti-EGFR therapy alone remains controversial. 
Current trials assessing combinations of molecular targeted agents have seen 
some promise. This chapter explores the background of BRAF mutation and 
current treatment strategies.
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1. Introduction
The RAS/RAF/MEK/ERK signalling cascade, also known as the MAPK 
(mitogen-activated protein kinase) pathway, is involved in cell proliferation, 
 differentiation, survival and apoptosis [1]. It receives input from multiple 
sources including internal metabolic stress and DNA damage pathways and altered 
protein concentrations as well as through signalling from external growth factors, 
cell-matrix interactions and communication from other cells [2]. This allows for a 
nodal point for therapeutic targeting, however, dysregulation of this pathway can 
also increase malignant behaviour [3].
Multiple signals activate RAS (KRAS, NRAS and HRAS), a family of GTPases. 
This, in turn, activates downstream RAF protein kinases (ARAF, BRAF and CRAF). 
The dominant substrates of RAF kinases are the MAPK/ERK kinases, MEK1 and 
MEK2. ERKs phosphorylate a variety of substrates, including multiple transcription 
factors that regulate several key cellular activities (Figure 1).
Mutations in RAS and RAF are the most common oncogenes in human cancer 
[4]. The focus of this chapter will be on BRAF mutations in colorectal cancer, in 
particular the V600E mutation, the clinical significance, molecular and clinical 
pathogenesis as well as treatment, now and into the future.
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2. BRAF
The RAF protein is made of three conserved regions: CR1, CR2 and CR3. CR1 
and CR2 are situated in the N terminus. CR1 acts as the main binding domain for 
RAS; CR2 is the regulatory domain. CR3 is situated in the C terminus and functions 
as the catalytic kinase domain. CR3 contains two regions important for RAF activa-
tion: the activation segment and the regulatory region [5]. Of the RAF family of 
protein kinases, BRAF is the most frequently mutated and remains the most potent 
activator of MEK.
The BRAF protooncogene, which encodes for the BRAF protein kinase, is located 
on chromosome 7 (q34) and is composed of 18 exons. There have been more than 
thirty BRAF mutations identified to date, occurring in various frequencies. The most 
common is BRAF V600E mutation (MT), which corresponds to a thymine to adenine 
transversion at position 1799, resulting in the substitution of valine by glutamate at 
position 600 of the protein [5]. This lies within the activating segment of the kinase 
domain. It renders BRAF constitutionally active, increasing kinase activity relative to 
BRAF wild-type (WT) by 10 times [6]. Because of this, co-mutations in the MAPK 
signalling cascade offers no selective advantage for developing tumours and there-
fore BRAF mutations are mutually exclusive with KRAS or NRAS mutations [7].
The V600E mutation accounts for more than 85% of BRAF mutations in mela-
noma, more than 50% of the mutations in non-small cell lung cancer and more 
than 95% of mutations in cholangiocarcinoma and hairy cell leukaemia. It accounts 
for more than 90% of BRAF mutations in colorectal cancer (CRC) [8]. Other 
BRAF mutations include R461I, I462S, G463E, G463V, G465A, G465E, G465V, 
G468A, G468E, N580S, E585K, D593V, F594L, G595R, L596V, T598I, V599D, V599E 
(V600E), V599K, V599R, V600K, and A727V [9].
Figure 1. 
The MAPK pathway [80].
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3. Prevalence and clinical features of BRAF MT CRC
BRAF mutations have been found in 7–10% of patients with metastatic CRC 
[7, 10]. BRAF MT CRC has been associated with a particular phenotype in mul-
tiple studies and meta-analysis and specifically pertaining to the BRAF V600E 
mutation. BRAF tumours are more prevalent in women and in patients >70 years 
of age. BRAF is not associated with age at diagnosis of less than 60 years [11]. 
BRAF mutation is more prevalent in proximal colon tumours and is rarely found 
in the left colon [7]. Histopathology also differs, with 60% of BRAF MT tumours 
being poorly differentiated and a higher rate of mucinous pathology [12]. There 
is an association with larger primary tumours. BRAF MT CRC is also associated 
with a high rate of peritoneal metastases and less lung and liver-limited disease 
[13–15]. In contrast, most non-V600 mutations were more likely to be lower 
grade and left-sided tumours with a greater overall survival [16, 17], except for 
codon 601/597 mutations which behave similarly to V600E MT CRC [18].
4. The serrated neoplastic pathway
The pathogenesis of CRC is a heterogeneous and complex process. The classic 
model of adenoma-carcinoma sequence was initially described by Vogelstein and 
accounts for approximately 80% of sporadic CRC [19]. Mutation of the tumour 
suppressor gene, APC, occurs early in the process and additional mutations and 
chromosomal instability leads to neoplastic progression [20].
The serrated neoplastic pathway is an alternative model of CRC pathogenesis 
with distinct morphologic and molecular characteristics. It is estimated about 20% 
of CRC develop via this pathway. These lesions develop from aberrant crypt foci 
and hyperplastic polyps (HP) into traditional serrated adenoma (TSA) and sessile 
serrated adenoma (SSA), with malignant potential. BRAF mutation occurs early in 
the pathway, shown to be present in HP, hyperplastic adenomas and SSA [21].
SSA are also characterised by the CpG island methylator phenotype (CIMP) [22]. 
A cytosine nucleotide followed by a guanine nucleotide (CpG dinucleotide) can be 
found in dense clusters (CpG islands) in the promoter regions of approximately 
half of all genes [23]. Aberrant hypermethylation of these CpG islands can lead to 
silencing of tumour suppressor genes that, in turn, lead to carcinogenesis. CIMP can 
be described as high, low or negative. Hypermethylation of the mismatch repair gene 
MLH1 results in microsatellite instability (MSI) in sporadic CRC [24].
MSI is implicated in 15% of sporadic CRC and >95% of Hereditary Non Polyposis 
Colorectal Cancer (HNPCC), also known as Lynch syndrome. It is caused by defi-
ciency of the DNA mismatch repair (MMR) system, composed of multiple interacting 
proteins including MSH2, MLH1. The majority of sporadic MSI high CRC is due to the 
hypermethylation of the mismatch repair gene MLH1 [25]. Sporadic MSI high CRC is 
also associated with BRAF mutation. BRAF mutations have been observed in 30–50% 
of MSI high CRC compared with 10% in microsatellite stable tumours [26, 27]. 
Germline mutations in 1 of 4 mismatch repair genes (MLH1, MSH2, MSH6 and PMS2) 
account for the majority of cases of HNPCC. BRAF mutations rarely occur in patients 
with germline mutations in MMR genes [28].
5. Prognostic significance of BRAF mutation
BRAF MT CRC is strongly associated with inferior survival compared with 
BRAF WT disease. Randomised control trials of first line treatment of meta-
static CRC demonstrate differences in OS of up to 12 months, shown in Table 1. 
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Study Treatment regimen Key outcomes in BRAF MT disease Prognostic 
finding
MRC 
FOCUS 
[76]
5-FU/irinotecan or 5-FU/
oxaliplatin
HR for OS 1.82 (P = 0.0002) BRAF predicts 
poor OS but no 
difference in 
PFS
MRC 
COIN [43]
Fluoropyrimidine/
oxaliplatin ± cetuximab
OS 8.8 vs. 20.1 months Median OS was 
significantly 
shorter in 
patients with 
BRAF, KRAS 
or NRAS 
mutations than 
in patients with 
WT KRAS, 
NRAS, and 
BRAF tumours, 
irrespective 
of treatment 
(P < 0.0001)
OPUS [77] FOLFOX ± cetuximab Median OS, 20.7 months with 
cetuximab + FOLFOX
Small numbers 
precluded 
definitive 
conclusions
CRYSTAL 
[78]
FOLFIRI ± cetuximab Median PFS (cetuximab + FOLFIRI 
vs. FOLFIRI), 8.0 vs. 5.6 months 
(HR, 0.934; P = 0.87)
Median OS, 14.1 vs. 10.3 months (HR 
0.908; P = 0.74)
BRAF MT was 
strong indicator 
of poor 
prognosis
NORDIC-
VII [48]
FLOX ± cetuximab BRAF MT had lower ORRs than 
BRAF WT (20 vs. 50%; P < 0.001)
BRAF 
mutations was a 
strong negative 
prognostic 
factor
PRIME 
[42]
FOLFOX ± panitumumab Median PFS: 
Panitumumab + FOLFOX vs. 
FOLFOX, 6.1 vs. 5.4 months
Median OS: 
Panitumumab + FOLFOX vs. 
FOLFOX, 10.5 vs. 9.2 months
BRAF mutation 
was a negative 
prognostic 
factor
CAIRO2 
[10]
Capecitabine + oxaliplatin  
+ bevacizumab vs. CAPOX  
+ bevacizumab + cetuximab
Lower median PFS, 5.9 and 
6.6 months in BRAF-MT vs. 12.2 and 
10.4 months in BRAF WT tumours 
with CAPOX + bevacizumab and 
CAPOX + bevacizumab + cetuximab, 
respectively
Lower median OS, 15.0 and 
15.2 months in BRAF MT vs. 24.6 and 
21.5 months in BRAF WT with CB 
and CBC, respectively
BRAF mutation 
was a negative 
prognostic 
marker
AGITG 
MAX [79]
Capecitabine ± bevacizumab Median OS, 20.8 months in BRAF 
WT vs. 8.6 months in BRAF MT 
tumours
BRAF mutation 
was a marker of 
poor prognosis 
irrespective of 
treatment
Table 1. 
BRAF mutation as a prognostic factor in clinical studies of first-line treatment of metastatic CRC.
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Venderbosch et al. reported a pooled analysis of the CAIRO, CAIRO2, COIN and 
FOCUS studies examining mismatch repair and BRAF status [29]. BRAF MT was 
associated with a poor prognosis with OS of 11.4 vs. 17.2 months, and PFS of 6.2 vs. 
7.7 months compared with BRAF WT. This analysis also found dMMR to indicate 
poor prognosis, despite significant evidence to show that MSI-high tumours confer 
a better prognosis. However, it is concluded that as there is no interaction between 
BRAF MT and dMMR, the poor prognostic value of dMMR is likely driven by BRAF 
MT. There was no difference in OS or PFS between dMMR BRAF MT and pMMR 
BRAF MT tumours. In a study examining RAS and BRAF mutations, BRAF patients 
had the worst overall survival. The median OS for WT, KRAS, NRAS and BRAF 
patients were 49.2, 36.2, 30.1 and 22.5 months, respectively [30].
Similarly, BRAF MT has been shown to be a negative prognostic factor in stage 
II and III disease. Data from the PETACC-3 was extracted, with KRAS, BRAF and 
MSI status examined [31]. MSI-high tumours were associated with better prognosis. 
BRAF MT was not prognostic of PFS. The MSI-high status appeared to attenuate the 
negative prognostic effect of BRAF MT on OS; BRAF MT is a negative prognostic 
factor in MSS CRC. However, more recently, a meta-analysis of 1164 patients with 
MSI-high non-metastatic CRC has shown that BRAF V600E mutation does correlate 
with adverse overall survival, but not disease recurrence [32].
Survival following metastasectomy is also worse for BRAF MT mCRC as dem-
onstrated in a meta-analysis of patients undergoing resection of liver metastases. 
It showed the BRAF mutation was negatively associated with OS (HR 3.055, 
P = 0.00004) [33].
In contrast, non-V600E BRAF mutations have a different prognosis. BRAF 
codons 594 and 596 mutations, when compared with V600E BRAF mutations, 
are more frequently rectal, non-mucinous with no peritoneal spread. In a study 
of 10 patients, all BRAF 594 and 596 tumours were microsatellite stable. OS was 
significantly longer (62 vs. 12.6 months, P = 0.002) [34]. Jones et al. identified 208 
metastatic CRC patients out of 9643 with non-V600E mutations. When compared 
with V600E BRAF mutation patients, those with non-V600E mutations were found 
to be younger, more likely male, and had lower grade tumours. In addition, median 
OS was significantly longer compared with both V600E BRAF mutant and BRAF 
wild-type patients (60.7 vs. 11.4 vs. 43 months respectively) [35]. This has also been 
demonstrated in a retrospective study of 98 patients, 6 of whom had non-V600E 
BRAF mutations. Although only a small sample size, OS was significantly better 
compared with V600E BRAF MT patients (P = 0.38) [17].
6. Treatment of BRAF-mutation CRC
6.1 Standard treatment
Doublet chemotherapy remains the standard of care for metastatic BRAF MT 
CRC in patients with appropriate performance status [36, 37]. First-line chemo-
therapy options include 5 fluorouracil, leucovorin and oxaliplatin (FOLFOX), 
5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and capecitabine plus 
oxaliplatin. A retrospective study reported no difference in median PFS between 
irinotecan-based or oxaliplatin-based chemotherapy regimens in the first line for 
BRAF-MT CRC [38].
A more intensive triplet chemotherapy regime has been proposed based on 5 fluo-
rouracil, leucovorin, oxaliplatin and irinotecan with bevacizumab (FOLFOXIRI+bev). 
A phase II trial of FOLFOXIRI and bevacizumab in the metastatic CRC population 
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showed a statistically significant benefit to progression free survival and trend towards 
improved overall survival at the expense of greater incidence of grade three toxici-
ties [39]. An exploratory analysis of the BRAF-MT cohort (25 patients in a pooled 
population) reported a median PFS of 11.8 months, median OS of 24.1 months and an 
impressive response rate of 72%, including one patient with complete response [40]. 
This was followed up by the open label phase III TRIBE study comparing FOLFIRI 
plus bevacizumab with FOLFOXIRI with bevacizumab [41]. In the molecular sub-
group analysis, 28 out of 391 cases were BRAF mutant. There was a trend towards 
benefit in overall survival (19.0 months in the FOLFOXIRI plus bevacizumab arm vs. 
10.7 months in the FOLFIRI plus bevacizumab arm, HR 0.54); however, this was not 
statistically significant. This was also seen in median PFS (7.5 vs. 9.5 months, HR 0.57) 
and best overall response (56 vs. 42%). While not statistically significant, this regime 
has been proposed in the first line setting for BRAF-MT mCRC patients with good 
performance status given the overall survival data.
6.2 EGFR inhibitors
The epidermal growth factor receptor (EGFR) is involved in signalling upstream 
of the RAS-RAF-MEK-ERK pathway. Monoclonal antibodies directed against 
EGFR, cetuximab and panitumumab have shown to be effective in metastatic CRC; 
however, KRAS mutation is a negative predictor of EGFR treatment response and 
upfront testing is recommended before starting treatment [36, 37].
As previously discussed, KRAS and BRAF mutations are mutually exclusive. 
Given the common signalling pathway, BRAF mutation has also been proposed to be 
a negative predictive marker of EGRF antibody treatment response. In the first line 
setting, the PRIME study evaluated the addition of panitumumab to FOLFOX. In 
BRAF-MT tumours, panitumumab added no benefit to survival (HR 0.9, P = 0.76) 
[42]. Similarly, the phase III MRC COIN trial showed no benefit in the addition of 
cetuximab to first-line oxaliplatin based chemotherapy, irrespective of KRAS or 
BRAF mutation status [43]. In the second line setting, the PICCOLO study reported 
no effect of panitumumab in combination with irinotecan on PFS, but a significant 
negative effect on OS (HR 1.84, P = 0.029). Cetuximab was also evaluated against 
best supportive care in the phase III CO.17 trial [44]. For BRAF MT tumours, there 
were no responses and no change to survival in the sample size of 13 (HR 0.84, 
P = 0.81).
Given the small numbers of BRAF-MT patients in these trials, there have been a 
number of meta-analyses evaluating the BRAF mutation as a predictive marker of 
EGFR therapy. Therkildsen et al. reviewed KRAS, NRAS, BRAF, PIK3CA and PTEN 
mutations in patients with KRAS exon 2 wild-type patients. Of the 1267 patients in 17 
studies treated with either cetuximab or panitumumab in both first line and subse-
quent like therapies, 128 patients had BRAF V600E mutations [45]. There was a signifi-
cant decrease in overall response rate (17 vs. 45%). BRAF mutation was also linked to 
shorter PFS (HR 2.95) and OS (HR 2.52) compared to BRAF wild-type tumours.
Pietrantonio et al. examined the impact of cetuximab and panitumumab on PFS, 
OS and overall response rate (ORR) [46]. This meta-analysis included 9 phase III 
trials and 1 phase II trial (across first-line, second-line and chemotherapy refractory 
settings). 463 RAS wild-type/BRAF MT CRC patients were identified. The addition 
of EGFR antibody therapy did not significantly improve PFS (HR 0.88, P = 0.33), 
OS (HR 0.91, P = 0.63) and ORR (relative risk 1.31, P = 0.25).
A further meta-analysis was published in 2015 but Rowland et al. [47]. It 
included 8 randomised control trials that had also been included in the analysis 
by Pietrantonio et al., but differed by excluding 2 trials; 1 by Tveit et al. [48] due 
to lack of OS and PFS data and Stintzing et al. [49] as the control arm included 
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bevacizumab. In addition, the statistical analysis differed as Rowland et al. com-
pared BRAF MT patients with BRAF wild-type. 351 patients were identified with 
BRAF mutation, of which 330 with the V600E mutation. The HR for PFS was 
0.86 for RAS wild-type/BRAF MT compared with 0.62 for RAS wild-type/BRAF 
wild-type tumours with a test of interaction that nears but does not reach statisti-
cal significance (P = 0.07). There was no difference for OS either, the HR for RAS 
wild-type/BRAF MT tumours was 0.97 compared with 0.81 for RAS wild-type/
BRAF wild-type (test of interaction, P = 0.43). It concluded that there was insuffi-
cient evidence to definitively state that RAS wild-type/BRAF MT individuals derive 
a different treatment benefit from EGFR antibodies compared with RAS wild-type/
BRAF wild-type patients.
More recently, the triplet chemotherapy regime, FOLFOXIRI, has been studied 
in combination with panitumumab in the VOLFI trial [50]. This was a randomised 
phase II trial of patients with RAS WT, unresectable metastatic CRC. 96 patients 
were included, of which, 16 patients with BRAF MT disease. The primary endpoint 
was ORR. The addition of panitumumab significantly improved ORR in the overall 
population (85.7 vs. 54.5%, P = 0.0013), and in the BRAF MT population, there was 
trend to improved ORR (71.4 vs. 22.2%, P = 0.1262).
Thus, while there exists a significant body of evidence that suggests minimal 
clinical benefit of EGFR antibody treatment in BRAF MT metastatic CRC, it is 
not definitive and therefore remains an option for therapy in discussion with the 
patient. This primarily relates to anti-EGFR as the sole biological agent however 
anti-EGFR therapy may have a definite role when combined with additional biologi-
cal agents such as BRAF inhibitors as discussed below.
6.3 BRAF inhibition in mCRC
BRAF represents a therapeutic target in cancer as, unlike KRAS, it is a rela-
tively unidirectional MEK-ERK effector. Inhibition of BRAF with vemurafenib 
(PLX4032) has been demonstrated to significantly benefit patients with unresect-
able or metastatic BRAF V600E MT melanoma, improving progression free survival 
and OS, with a response rate of 48% [51]. In sharp contrast, BRAF inhibition in 
mCRC is disappointing. An expansion phase II study examined vemurafenib in 
patients with BRAF MT mCRC who have had at least one line of prior therapy [52]. 
Of the 21 patients treated, 1 patient had a partial response and 7 other patients had 
stable disease by RESIST criteria. The median PFS was only 2.1 months and ORR of 
5%. Although there were signs of efficacy, the authors concluded that single-agent 
vemurafenib did not show any meaningful clinical activity in patients with BRAF 
V600E MT mCRC.
These results were similar to a histology-independent phase II “basket” trial of 
vemurafenib. 122 patients with BRAF V600 MT malignancies were enrolled into 
7 prespecified cohorts, including 37 with mCRC [53]. Vemurafenib, as a single 
agent, was given to 10 patients with mCRC. Response was poor, with 50% having 
stable disease and the rest progressing on therapy. The remaining 27 patients with 
mCRC received combination of vemurafenib and cetuximab, and the results will be 
discussed later in the chapter.
There are several mechanisms of resistance identified that reduce the efficacy 
of BRAF inhibition in mCRC. For example Prahallad et al. identified that BRAF 
inhibition with vemurafenib in mCRC cells causes a rapid activation of EGFR 
through an ERK-dependent negative feedback loop [54]. Unlike in melanoma, CRC 
cell lines express high levels of activated EGFR. Blockade of EGFR with either EGFR 
monoclonal antibodies or small-molecule kinase inhibitors (gefitinib and erlotinib) 
was showed to work synergistically with BRAF inhibition.
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More recently, it has been showed that BRAF inhibition can also lead to up 
regulation of other receptor tyrosine kinases including human epidermal growth 
factor receptor (HER) 2 and HER3 [55].
Activation of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway has 
also been implicated in BRAF inhibition resistance [56]. PI3K signalling is activated 
by direct mutational activation or amplification of PIK3CA and AKT1 or loss of 
PTEN [57]. Approximately 40% of CRC have been shown to have alterations in 1 
of 8 PI3K pathway genes, which are almost always mutually exclusive to each other 
[58]. Genotyping of BRAF MT CRC has showed concomitant PI3KCA and PTEN 
mutations [59].
The Wnt/β-catenin pathway is also involved in cell proliferation, differentia-
tion and survival and interacts with the RAS-RAF-MEK-ERK pathway at multiple 
points. It has been identified as an important step in tumourigenesis and alterations 
in the Wnt pathway have been identified more frequently in BRAF V600E MT CRC 
patient samples, potentially representing an alternative pathway of tumour devel-
opment when BRAF is inhibited [60].
Based on these findings, BRAF inhibition has been combined with a number 
of different agents in order to attempt to overcome resistance and improve 
response.
6.4 BRAF and EGFR inhibition
In the fore-mentioned phase II “basket” trial, the effect of vemurafenib and 
cetuximab evaluated in 27 patients with BRAF V600 MT mCRC. The result was 
marginally improved compared to single-agent treatment. One patient had a partial 
response (4% ORR) and 69% had stable disease. Median PFS was 3.7 months and 
median OS was 7.1 months. A pilot trial with combination panitumumab and 
vemurafenib included 15 patients with BRAF V600E mCRC who had received at 
least 1 prior line of therapy [61]. 2 patients had confirmed partial response and 6 
patients had stable disease, including 2 patients with stability lasting over 6 months. 
The treatment was well tolerated with fatigue and rash being the most frequently 
observed adverse events.
Other combinations of BRAF and EGFR inhibitors have also been investigated 
including vemurafenib plus erlotinib [62], encorafenib (LGX818, a highly selective 
ATP-competitive small molecule RAF kinase inhibitor) plus cetuximab [63] and 
dabrafenib (a small molecule kinase BRAF inhibitor) plus panitumumab [64]. 
Response rates in these trials range from 4 to 23%. To improve this outcome, the 
combination has been combined with chemotherapy in the randomised phase 2 
SWOG 1406 study [65]. Interim results of this trial were presented in 2017. The 
combination of irinotecan and cetuximab with or without vemurafenib was exam-
ined in 106 patients. Median PFS was significantly improved with the addition of 
vemurafenib (4.4 vs. 2.0 months, P < 0.001). Response rate increased from 4 to 16% 
(P = 0.09). However, there was an increase in grade 3 and 4 adverse events includ-
ing neutropenia, anaemia and nausea. It was noted that no new safety signals. The 
data on median OS was immature. Based on these findings, this treatment regime 
has been included in treatment guidelines [36].
6.5 BRAF and MEK inhibition
BRAF and MEK inhibition has been combined in melanoma with greater effi-
cacy and so has been evaluated in the BRAF MT mCRC population. 43 patients were 
treated with dabrafenib and trametinib [66]. 1 patient achieved a complete response 
and 4 patients had a partial response (ORR 12%). 24 patients achieved stable 
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disease (56%). During-treatment biopsies in 9 patients showed reduced levels of 
ERK compared with pre-treatment biopsies. It is suggested that combination BRAF 
and MEK inhibition could be a potential therapeutic backbone for the addition of 
other agents including EGFR inhibitors.
6.6 BRAF, MEK and EGFR inhibition
Given the role of MEK and ERK in EGFR activation leading to BRAF inhibitor 
resistance, the triplet combination of BRAF, MEK and EGFR inhibitors have been 
investigated. Corcoran et al. reported on a trial involving 3 cohorts, dabrafenib and 
panitumumab (n = 20), dabrafenib, trametinib and panitumumab (n = 91), and 
trametinib and panitumumab (n = 31) [67].
The ORR for triplet therapy was 21%, compared with 0% with trametinib and 
panitumumab and 10% with dabrafenib and panitumumab. With the increase in 
response rate, there was also a corresponding increase in adverse events. 70% of 
patients on triplet therapy had a grade 3 or 4 adverse event. 18% of patients had an 
adverse event resulting in study discontinuation, 54% had an adverse event that 
resulted in dose reduction, and 71% of patients had an adverse event that led to 
dose interruption or delay. Skin toxicity including rash and dermatitis acneiform 
occurred in 90% of patients, with 21% having grade 3 or 4 adverse events. Paired 
pre-treatment and on-treatment biopsies demonstrated that triplet combination 
produced greater inhibition of ERK than the dabrafenib and panitumumab doublet 
or the dabrafenib and panitumumab doublet.
It has been suggested that BRAF inhibitors may offset the dermatologic toxicity 
resulting from MEK or EGFR inhibitors. Mondaca et al. reported on a case of BRAF 
V600E MT metastatic CRC on clinical trial with dabrafenib, trametinib and pani-
tumumab [68]. Dabrafenib dose reductions for neutropenia were associated with 
increased skin toxicity, which subsequently improved with increasing the dose. This 
case highlights the importance of dose intensity of BRAF inhibitors with used in 
combination regimens.
6.7 Other therapeutic strategies and current trials
Current therapeutic investigations in the BRAF MT mCRC field involve multiple 
targeted therapies aimed at overcoming acquired resistance to MAPK pathway 
inhibition.
One such combination is encorafenib, cetuximab and alpelisib. Alpelisib 
(BYL719) specifically inhibits the alpha subunit of PI3K. A phase 1b dose escala-
tion study included 2 arms, encorafenib plus cetuximab vs. triplet therapy with 
encorafenib, cetuximab and alpelisib [69]. Triplet therapy was showed to be 
active with an ORR of 18% and impressively a disease control rate of 92.8%. This 
combination has been investigated further in a phase 2 trial [63]. 102 patients 
with refractory BRAF MT CRC were randomised to doublet or triplet therapy. 
Progression free survival was the primary endpoint. Interim data following 73 
events were released and showed no statistical difference between doublet and 
triplet therapy with HR 0.69 (P = 0.064) and median PFS of 4.2 vs. 5.4 months. 
Grade 3 and 4 adverse events were higher in the triplet arm, including anaemia 
and hyperglycaemia. Further investigations with other PI3K inhibitors are 
currently underway; however, the efficacy of PI3K inhibition remains unclear 
(NCT01337765, NCT01363232).
Other potential targets include BRAF and AKT inhibition [70], BRAF, EGFR 
and HER2 inhibition [55], ERK inhibition alone or in combination with BRAF 
inhibition [71] and Wnt/β-catenin pathway inhibition (NCT02278133) Table 2.
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Immunotherapy also plays a role in the management of metastatic CRC [36]. 
Pembrolizumab and nivolumab are immune check point inhibitors against pro-
grammed death 1 (PD-1) that have demonstrated significant activity against 
MSI-high mCRC [72, 73]. Given the strong association between MSI-high and BRAF 
MT CRC, this represents a possible therapeutic option. The initial trial of pembro-
lizumab in MSI-high CRC did not include BRAF MT cases; however, a case report 
does suggest activity in the MSI-high BRAF MT population [74].
Nivolumab and combination nivolumab with ipilimumab (cytotoxic T-lymphocyte 
associated protein 4 inhibitor) in MSI-high/dMMR CRC was examined in the phase 
2 CheckMate 142 study [73, 75]. 12 of the 74 patients receiving nivolumab harboured 
a BRAF mutation. An objective response was seen in 3 patients (25%) and 9 patients 
achieved disease control for greater than 12 weeks. The ORR for combination immu-
notherapy was greater at 55% in patients with MSI-high BRAF MT CRC, and disease 
control rate of 79%. Safety data was not reported by mutation status, however, 
appeared manageable, with 32% experiencing a grade 3 or 4 adverse event, most com-
monly raised AST. Discontinuation due to a treatment related adverse event was 13%.
7. Conclusion
BRAF V600E mutations are present in 7–10% of CRC. It represents a population 
with poor prognosis and a particular clinical phenotype, being more prevalent in 
ClinicalTrials.
gov number
Therapeutic 
strategy
Agents investigated Study 
design
Status
NCT02928224 BRAF + EGFR  
+ MEK inhibition
Encorafenib + cetuximab ±  
binimetinib
Phase 3, 
randomised, 
open label
Recruiting
NCT02906059 Chemotherapy 
 + selective Wee 1 
inhibitor
Irinotecan + AZD1775 Phase 1b Recruiting
NCT01351103 PORCN inhibitor 
 + immunotherapy
LGK974 ± PDR001 Phase 1 Recruiting
NCT01640405 Antiangiogenesis 
agent + cytotoxic 
chemotherapy
FOLFOX + bevacizumab vs. 
FOLFOXIRI + bevacizumab
Phase 3 open 
label
Active, not 
recruiting
NCT01750918 BRAF + EGFR  
+ MEK inhibition
Dabrafenib + panitumumab 
vs. dabrafenib + trametinib 
 + panitumumab
Dabrafenib + panitumumab 
vs. dabrafenib  
+ trametinib + panitumumab 
vs. 5-fluorouracil-based 
chemotherapy + monoclonal 
antibody
Trametinib + panitumumab
4 part phase 
1/2, open 
label
Active, not 
recruiting
NCT01719380 BRAF + EGFR  
+ PI3K inhibition
Encorafenib + cetuximab 
 + alpelisib
Phase 
1b/2, open 
label, dose 
escalation
Active, not 
recruiting
Updated 7th November 2018.
Table 2. 
Ongoing studies investigating different treatment strategies for BRAF MT mCRC.
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women, older than 70 years of age, associated with poorly differentiated histology 
and right-sided tumours. Chemotherapy with the addition of anti-angiogenesis 
agent remains the current standard of care in the first line metastatic setting. More 
aggressive, triplet chemotherapy (FOLFOXIRI) may be appropriate in the selected 
patient. BRAF inhibition has been extensively investigated for second line therapy 
and beyond and when in combination with EGFR, MEK and PI3K inhibitors have 
increased response rates, however, PFS and OS remains poor. Ongoing research 
remains important to improve outcomes in BRAF MT CRC.
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